VIDEO: 'Encouraging' real-world data on CAR-T for multiple myeloma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

CAR-T, the new things are new targets. You know, initially the two CAR-T that we have now are targeted through the BCMA, and we know that those products provide good responses, and actually really good responses for heavily pre-treated patients. Though some patients lose those responses, and still patients relapse after they receive the CAR-T product. Focus was into looking into new targets that may be beneficial for patients who already progressed on the previous targets, on specifically BCMA. So we're seeing a study on the APRC5D target, that we have a bispecific antibody now on development for, with few number of patients from China and looking into the responses on specifically this target. And it seems to be promising in this early phase study, where those patients were heavily pre-treated, they got multiple lines of therapies before, and though they responded well to this product. We also saw combining targets, doing more epitopes onto the CAR-T, and also looking into CD19/BCMA kind of dual approach. Those new approaches will be helpful, because it may provide more options after progression on the previous CAR-T. It also hopefully will provide us more options to give for patients, because there's lots of delay on using commercial CAR-Ts now, for patients who need them. You know, real-world data on CAR-T now is evolving. We have more information, as we speak. There was one presentation in ASCO looking into multi-center experience providing those CAR-T products in multiple myeloma. And I think the results are encouraging. First, the manufacturing failure was relatively low, around 4%. And patients who received the product have around 80 to 83% overall response rate, which is consistent with what the previous study reported. So this is important, because the responses were kind of similar, and also the manufacturing component, which we worry sometimes about, was also within things that we expected to see. So all in all, when we use those products in real life, they work, I think we need just to work to make sure that patients have better access to them, and improve our capabilities of doing those CAR-Ts, and providing them to patients.